Showing results (1181-1190 of 2,331) with videos related to

Sort By:
Pageof 234
Clinical Drug Investigation|October 28, 2024
Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter StudyClara Aguirre, Ana Alonso-Torres, Eduardo Agüera, et al.
Clinical Drug Investigation|November 5, 2025
Cost-Effectiveness of Sacituzumab Govitecan and Physician's Choice of Treatment in Patients with Metastatic Triple Negative Breast Cancer in SpainSilvia Fenix-Caballero, Emilio Jesús Alegre Del Rey, Zuzana Špacírová, et al.
Clinical Drug Investigation|November 3, 2025
Trends of Opioids and Nefopam Use Among French Children: A Population-Based Study From 2009 to 2023Sandrella Hamdan, Pierre Pinson, Jean-Marc Tréluyer, et al.
Clinical Drug Investigation|October 8, 2025
Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report DatabaseYuko Kanbayashi, Risa Morioka, Keiko Hosohata
Clinical Drug Investigation|October 9, 2025
Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label TrialDongmei Ji, Shufang Wang, Wei Yao, et al.
Clinical Drug Investigation|October 15, 2025
The Effects of a Bacopa monnieri Extract (Bacumen®) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled TrialA L Lopresti, S J Smith
Clinical Drug Investigation|October 2, 2025
Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS TrialXavier Barreau, René Anxionnat, Olivier Heck, et al.
Clinical Drug Investigation|May 25, 2024
An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United KingdomPablo E Bretos-Azcona, Matthew Wallace, Murvin Jootun, et al.
Clinical Drug Investigation|December 17, 2020
First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy SubjectsKhalid Abd-Elaziz, Christine Voors-Pette, Kang-Ling Wang, et al.
Clinical Drug Investigation|December 28, 2020
Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese SubjectsJinjie He, Guoying Cao, Jicheng Yu, et al.
Pageof 234